Remove 2028 Remove Drug Development Remove Vaccines
article thumbnail

US companies drive 2023 drug launches positioned for blockbuster success by 2028

Pharmaceutical Technology

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Vaccines 105
article thumbnail

STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion

STAT

The announcement was made ahead of a meeting being held by Moderna on Thursday to update investors on its research and development efforts. The company also said that it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. Continue to STAT+ to read the full story…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Accelerating AMR vaccine development

European Pharmaceutical Review

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development.

Vaccines 115
article thumbnail

Can your LNP manufacturing platform cope with the pace of the mRNA revolution?

Pharmaceutical Technology

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. billion by 2028. Excluding vaccines, there are five mRNA therapeutic products in clinical trial development as of November 2022.